AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC)

Phase 2

Completed

Conditions: Opioid Induced Constipation (OIC)

Interventions: Drug: placebo
Drug: NKTR-118

First Posted Date: 2008-01-24

Last Posted Date: 2015-06-12

Lead Sponsor: AstraZeneca

Target Recruit Count: 207

Registration Number: NCT00600119

Locations: 🇺🇸
Northwest Clinical Trials, Boise, Idaho, United States
🇺🇸
Investigative Clinical Research of Indiana, LLC, Indianapolis, Indiana, United States
🇺🇸
Pain & Rehabilitation Clinic of Chicago, Chicago, Illinois, United States

and more 30 locations

Quality of Life in Schizophrenic Patients

Completed

Conditions: Schizophrenia

First Posted Date: 2008-01-17

Last Posted Date: 2010-06-09

Lead Sponsor: AstraZeneca

Target Recruit Count: 124

Registration Number: NCT00597168

Locations: 🇧🇪
Research Site, Woluwe-Saint-Lambert, Belgium

Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer

Phase 3

Completed

Conditions: Gastric Ulcer
Duodenal Ulcer
Rheumatoid Arthritis
Osteoarthritis
Lumbago

Interventions: Drug: Esomeprazole 20 mg

First Posted Date: 2008-01-16

Last Posted Date: 2012-09-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 395

Registration Number: NCT00595517

Locations: 🇯🇵
Research Site, Tokyo, Japan

A Phase-II Study Of TOMUDEX Plus Radiotherapy In Subject With Inoperable or Recurrent Rectal Cancer

Phase 2

Completed

Conditions: Inoperable or Recurrent Rectal Cancer

First Posted Date: 2008-01-10

Last Posted Date: 2008-01-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 49

Registration Number: NCT00590278

Locations: 🇹🇷
Research Site, Istanbul, Turkey

Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX

Phase 4

Completed

Conditions: Prostate Cancer

First Posted Date: 2008-01-10

Last Posted Date: 2008-01-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 125

Registration Number: NCT00590213

Locations: 🇹🇷
Research Site, Samsun, Turkey

Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly

Phase 1

Completed

Conditions: Dyslipidemia, Renal Insufficiency

Interventions: Drug: ABT-335
Drug: Rosuvastatin

First Posted Date: 2008-01-03

Last Posted Date: 2012-09-28

Lead Sponsor: AstraZeneca

Target Recruit Count: 37

Registration Number: NCT00585143

Locations: 🇺🇸
Site Reference ID/Investigator# 6738, Miami, Florida, United States
🇺🇸
Site Reference ID/Investigator# 7723, Minneapolis, Minnesota, United States
🇺🇸
Site Reference ID/Investigator# 8280, Richmond, Virginia, United States

and more 3 locations

A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma

Phase 1

Terminated

Conditions: Melanoma

Interventions: Drug: CP-675,206

First Posted Date: 2008-01-02

Last Posted Date: 2012-06-06

Lead Sponsor: AstraZeneca

Target Recruit Count: 49

Registration Number: NCT00585000

Locations: 🇺🇸
Research Site, Durham, North Carolina, United States

Exenatide Pregnancy Registry - Type 2 Diabetes in Pregnancy

Terminated

Conditions: Preterm Birth
Birth Defects
Type 2 Diabetes

First Posted Date: 2007-12-21

Last Posted Date: 2016-05-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 7

Registration Number: NCT00579150

Locations: 🇺🇸
Research Site, Wilmington, North Carolina, United States

An Observational Study to Investigate How Patients Experience the Ability to Adjust Their Asthma Maintenance Medication

Completed

Conditions: Asthma

First Posted Date: 2007-12-20

Last Posted Date: 2011-01-28

Lead Sponsor: AstraZeneca

Registration Number: NCT00577265

Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)

Phase 3

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: placebo
Drug: exenatide

First Posted Date: 2007-12-20

Last Posted Date: 2015-04-09

Lead Sponsor: AstraZeneca

Target Recruit Count: 181

Registration Number: NCT00577824

Locations: 🇯🇵
Research Site, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy